=> d his ful

```
     FILE 'HCAPLUS' ENTERED AT 11:51:40 ON 04 JUN 2004
                E PRIESTLEY E SCOTT/AU
L1           18 SEA ABB=ON  "PRIESTLEY E SCOTT"/AU
                E DECICCO CARL P/AU
L2          123 SEA ABB=ON  ("DECICCO C P"/AU OR "DECICCO CARL"/AU OR "DECICCO
                CARL P"/AU OR "DECICCO CARL PETER"/AU)
L3            4 SEA ABB=ON  L1 AND L2
                SELECT RN L3 1-4


     FILE 'REGISTRY' ENTERED AT 11:53:10 ON 04 JUN 2004
L4          221 SEA ABB=ON  (149885-80-3/BI OR 18680-27-8/BI OR 103-71-9/BI OR
                106-95-6/BI OR 108-98-5/BI OR 1149-26-4/BI OR 119479-32-2/BI
                OR 124-63-0/BI OR 126689-01-8/BI OR 130653-09-7/BI OR 131357-48
                -7/BI OR 131433-93-7/BI OR 13734-41-3/BI OR 146949-07-7/BI OR
                15028-39-4/BI OR 1623-93-4/BI OR 17193-39-4/BI OR 172096-96-7/B
                I OR 1730-25-2/BI OR 1899-93-0/BI OR 274918-51-3/BI OR
                3182-79-4/BI OR 319009-74-0/BI OR 319009-76-2/BI OR 319009-78-4
                /BI OR 319009-80-8/BI OR 319009-82-0/BI OR 319009-90-0/BI OR
                319009-92-2/BI OR 319009-94-4/BI OR 319009-96-6/BI OR 319009-98
                -8/BI OR 319010-99-6/BI OR 319011-02-4/BI OR 319011-08-0/BI OR
                319011-10-4/BI OR 319011-16-0/BI OR 319011-18-2/BI OR 319011-22
                -8/BI OR 319011-25-1/BI OR 319011-27-3/BI OR 319011-29-5/BI OR
                323196-84-5/BI OR 323196-85-6/BI OR 323196-86-7/BI OR 323196-87
                -8/BI OR 323196-88-9/BI OR 323196-89-0/BI OR 323196-90-3/BI OR
                323196-91-4/BI OR 323196-92-5/BI OR 323196-93-6/BI OR 323196-94
                -7/BI OR 323196-95-8/BI OR 323196-96-9/BI OR 323196-97-0/BI OR
                323196-98-1/BI OR 323196-99-2/BI OR 323197-00-8/BI OR 323197-01
                -9/BI OR 323197-02-0/BI OR 323197-03-1/BI OR 323197-04-2/BI OR
                323197-05-3/BI OR 323197-06-4/BI OR 323197-07-5/BI OR 323197-08
                -6/BI OR 323197-09-7/BI OR 323197-10-0/BI OR 323197-11-1/BI OR
                323197-12-2/BI OR 323197-13-3/BI OR 323197-14-4/BI OR 323197-15
                -5/BI OR 323197-16-6/BI OR 323197-17-7/BI OR 323197-18-8/BI OR
                323197-19-9/BI OR 323197-20-2/BI OR 323197-21-3/BI OR 323197-22
                -4/BI OR 323197-23-5/BI OR 323197-24-6/BI OR 323197-25-7/BI OR
                323197-26-8/BI OR 323197-27-9/BI OR 323197-28-0/BI OR 323197-29
                -1/BI OR 323197-30-4/BI OR 323197-31-5/BI OR 323197-32-6/BI OR
                323197-33-7/BI OR 323197-34-8/BI OR 323197-35-9/BI OR 323197-36
                -0/BI OR 323197-37-1/BI OR 323197-38-2/BI OR 323197-39-3/BI OR
                323197-40-6/BI OR 323197-41-7/BI OR 323197-42-8/BI OR 323197-43
                -9/BI OR 323197-44-0/BI OR 323197-45-1/BI OR 323197-46-2/BI OR
                323197-47-3/BI OR 323197-48-4/BI OR 323197-58-6/BI OR 323197-73
                -5/BI OR 323197-74-6/BI OR 359-07-9/BI OR 38329-34-9/BI OR
                42918-86-5/BI OR 4333-56-6/BI OR 460-

     FILE 'HCAPLUS' ENTERED AT 11:53:53 ON 04 JUN 2004
L5            4 SEA ABB=ON  L3 AND L4

     FILE 'REGISTRY' ENTERED AT 12:11:45 ON 04 JUN 2004
L6              STR
L7            0 SEA SSS SAM L6
L8            1 SEA SSS FUL L6
L9              STR L6
L10           0 SEA SSS SAM L9

     FILE 'HCAPLUS' ENTERED AT 12:22:40 ON 04 JUN 2004
L11           2 SEA ABB=ON  L8
```

'compd. from Registry, see d que stat

2 cits from CA Plus

FILE 'CAOLD' ENTERED AT 12:49:26 ON 04 JUN 2004
L12 0 SEA ABB=ON L8 O Jun CA Old

```
=> d que stat l11
L6                  STR
```




```
REP G1=(1-3) CH2
VAR G2=H/C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  16

STEREO ATTRIBUTES: NONE
L8             1 SEA FILE=REGISTRY SSS FUL L6
L11            2 SEA FILE=HCAPLUS ABB=ON  L8
```

=> d ibib abs hitstr l11 1-2

L11 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:23525 HCAPLUS
DOCUMENT NUMBER: 138:90078
TITLE: Preparation of lactam acylaminoalkaneboronates as inhibitors of hepatitis C virus NS3 protease.
INVENTOR(S): Priestley, E. Scott; Decicco, Carl P.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 45 pp., Cont.-in-part of U.S. Ser. No. 626,286, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003008828	A1	20030109	US 2001-10184	20011206

PRIORITY APPLN. INFO.: US 1999-145631P P 19990726
US 2000-626286 B2 20000725
OTHER SOURCE(S): MARPAT 138:90078
GI



I

AB Title compds. I [X = B(OH)2, BY1Y2, COCONHR1a; Y1, Y2 = OH, F, amino, alkoxy; BY1Y2 = atoms to form a cyclic boron ester, amide, or amide-ester containing 2-20 C atoms and optionally 1-3 N, O, or S atoms; R1, R1a = (substituted) alkyl, alkenyl, alkynyl, cycloalkyl; R2 = H; R1R2C = cycloalkyl; R3 = (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, Ph, naphthyl, heteroaryl; R4 = H, (substituted) alkyl, Ph, PhCH2, PhCH2CH2; R5 = H, QR5a; Q = chain of 0-3 amino acids; R5a = SOR6, SO2R6, COR6, CO2R8, etc.; R6 = (substituted) alkyl, Ph, naphthyl, PhCH2, heteroaryl; R8 = alkyl, PhCH2, cycloalkylmethyl; Z = (CH2)1-3] were prepared as inhibitors of hepatitis C virus NS3 protease. Thus, (1R)-1-[[(2S)-3-cyclohexyl-2-[3-isopropyl-3-[[(2S)-3-methyl-2-[(2-pyrazinylcarbonyl)amino]butanoyl]amino]-2-oxo-1-pyrrolidinyl]propanoyl]amino]-3-butenylboronic acid (+)-pinanediol ester was prepared by solution phase chemical A number of I inhibited hepatitis C virus NS3 protease with Ki <60 μM.

IT **323196-93-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of lactam acylaminoalkaneboronates as inhibitors of hepatitis C virus NS3 protease)
RN 323196-93-6 HCAPLUS
CN Boronic acid, [(1R)-1-[[(2S)-3-cyclohexyl-2-[3-(1-methylethyl)-3-[[(3-

methylphenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:78359 HCAPLUS
DOCUMENT NUMBER: 134:147855
TITLE: Preparation of lactam acylaminoalkaneboronates as inhibitors of hepatitis C virus NS3 protease.
INVENTOR(S): Priestley, E. Scott; Decicco, Carl P.
PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA
SOURCE: PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001007407	A1	20010201	WO 2000-US20189	20000726
W: AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1206449	A1	20020522	EP 2000-950642	20000726
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				

PRIORITY APPLN. INFO.: US 1999-145631P P 19990726
WO 2000-US20189 W 20000726
OTHER SOURCE(S): MARPAT 134:147855
GI



I

AB Title compds. [I; X = B(OH)2, BYY1, COCONHR1a; Y1, Y2 = OH, F, amino, alkoxy; BY1Y2 = atoms to form a cyclic boron ester, amide, or amide-ester containing 2-20 C atoms and optionally 1-3 N, O, or S atoms; R1, R1a = (substituted) alkyl, alkenyl, alkynyl, cycloalkyl; R2 = H; R1R2C = cycloalkyl; R3 = (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, Ph, naphthyl, heteroaryl; R4 = H, (substituted) alkyl, Ph, PhCH2, PhCH2CH2; R5 = H, QR5a; Q = chain of 0-3 amino acids; R5a = SOR6, SO2R7, COR6, CO2R8; R6 = (substituted) alkyl, Ph, naphthyl, PhCH2, heteroaryl; R7 = H, alkyl; R8 = alkyl, PhCH2, cycloalkylmethyl; Q = (CH2)1-3], were prepared Thus, (1R)-1-[[(2S)-3-cyclohexyl-2-[3-isopropyl-3-[[(2S)-3-methyl-2-[(2-pyrazinylcarbonyl)amino]butanoyl]amino]-2-oxo-1-pyrrolidinyl]propanoyl]amino]-3-butenylboronic acid (+)-pinanediol ester was prepared by solution phase chemical A number of I inhibited hepatitis C virus NS3 protease with Ki<60 μM.

IT **323196-93-6P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of lactam acylaminoalkaneboronates as inhibitors of hepatitis C virus NS3 protease)

RN 323196-93-6 HCAPLUS

CN Boronic acid, [(1R)-1-[[(2S)-3-cyclohexyl-2-[3-(1-methylethyl)-3-[[(3-methylphenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitstr l5 1-4

L5 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:23525 HCAPLUS
DOCUMENT NUMBER: 138:90078
TITLE: Preparation of lactam acylaminoalkaneboronates as inhibitors of hepatitis C virus NS3 protease.
INVENTOR(S): **Priestley, E. Scott; Decicco, Carl P.**
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 45 pp., Cont.-in-part of U.S. Ser. No. 626,286, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003008828	A1	20030109	US 2001-10184	20011206
PRIORITY APPLN. INFO.:			US 1999-145631P P	19990726
			US 2000-626286 B2	20000725

OTHER SOURCE(S): MARPAT 138:90078
GI



I

AB Title compds. I [X = B(OH)2, BY1Y2, COCONHR1a; Y1, Y2 = OH, F, amino, alkoxy; BY1Y2 = atoms to form a cyclic boron ester, amide, or amide-ester containing 2-20 C atoms and optionally 1-3 N, O, or S atoms; R1, R1a = (substituted) alkyl, alkenyl, alkynyl, cycloalkyl; R2 = H; R1R2C = cycloalkyl; R3 = (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, Ph, naphthyl, heteroaryl; R4 = H, (substituted) alkyl, Ph, PhCH2, PhCH2CH2; R5 = H, QR5a; Q = chain of 0-3 amino acids; R5a = SOR6, SO2R6, COR6, CO2R8, etc.; R6 = (substituted) alkyl, Ph, naphthyl, PhCH2, heteroaryl; R8 = alkyl, PhCH2, cycloalkylmethyl; Z = (CH2)1-3] were prepared as inhibitors of hepatitis C virus NS3 protease. Thus, (1R)-1-[[(2S)-3-cyclohexyl-2-[3-isopropyl-3-[[(2S)-3-methyl-2-[(2-pyrazinylcarbonyl)amino]butanoyl]amino]-2-oxo-1-pyrrolidinyl]propanoyl]amino]-3-butenylboronic acid (+)-pinanediol ester was prepared by solution phase chemical A number of I inhibited hepatitis C virus NS3 protease with Ki <60 μM.

IT **149885-80-3**
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(inhibitors; preparation of lactam acylaminoalkaneboronates as inhibitors of hepatitis C virus NS3 protease)

RN 149885-80-3 HCAPLUS
CN Proteinase, polyprotein-processing, NS3 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **323196-84-5P 323196-85-6P 323196-86-7P**
323196-87-8P 323196-88-9P 323196-89-0P
323196-90-3P 323196-91-4P 323196-92-5P
323196-93-6P 323196-94-7P 323196-95-8P
323196-96-9P 323196-97-0P 323196-98-1P
323196-99-2P 323197-00-8P 323197-01-9P
323197-02-0P 323197-03-1P 323197-04-2P
323197-05-3P 323197-06-4P 323197-07-5P
323197-08-6P 323197-09-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of lactam acylaminoalkaneboronates as inhibitors of hepatitis C virus NS3 protease)

RN 323196-84-5 HCAPLUS
CN Pyrazinecarboxamide, N-[(1S)-1-[[[1-[(1S)-1-(cyclohexylmethyl)-2-[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-butenyl]amino]-2-oxoethyl]-3-(1-methylethyl)-2-oxo-3-pyrrolidinyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323196-85-6 HCAPLUS
CN Pyrazinecarboxamide, N-[(1S)-1-[[[1-[(1S)-1-(cyclohexylmethyl)-2-[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-butenyl]amino]-2-oxoethyl]-3-(1-methylethyl)-2-oxo-3-piperidinyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323196-86-7 HCAPLUS
CN 1H-Azepine-1-acetamide, N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]hexahydro-3-[(methylsulfonyl)amino]-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323196-87-8 HCAPLUS
CN 1-Pyrrolidineacetamide, 3-amino-α-(cyclohexylmethyl)-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-2-oxo-, monohydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 323196-88-9 HCAPLUS
CN 1-Pyrrolidineacetamide, 3-[([1,1'-biphenyl]-4-ylsulfonyl)amino]-α-(cyclohexylmethyl)-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-2-oxo-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323196-89-0 HCAPLUS
CN 1-Pyrrolidineacetamide, α-(cyclohexylmethyl)-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-2-oxo-3-[[(4-propylphenyl)sulfonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323196-90-3 HCAPLUS
CN 1-Pyrrolidineacetamide, α-(cyclohexylmethyl)-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-3-[(1-naphthalenylsulfonyl)amino]-2-oxo-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323196-91-4 HCAPLUS
CN 1-Pyrrolidineacetamide, α-(cyclohexylmethyl)-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-2-oxo-3-[[(phenylamino)carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323196-92-5 HCAPLUS
CN 1-Pyrrolidineacetamide, α-(cyclohexylmethyl)-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-3-[[(3-methylphenyl)sulfonyl]amino]-2-oxo-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323196-93-6 HCAPLUS
CN Boronic acid, [(1R)-1-[[(2S)-3-cyclohexyl-2-[3-(1-methylethyl)-3-[[(3-methylphenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323196-94-7 HCAPLUS
CN Carbamic acid, [1-[(1S)-2-[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]amino]-2-oxo-1-phenylethyl]-3-(1-methylethyl)-2-oxo-3-pyrrolidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323196-95-8 HCAPLUS
CN 1-Pyrrolidineacetamide, 3-amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-2-oxo-α-phenyl-, monohydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 323196-96-9 HCAPLUS
CN 1-Pyrrolidineacetamide, N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-3-[(methylsulfonyl)amino]-2-oxo-α-phenyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323196-97-0 HCAPLUS
CN 1-Pyrrolidineacetamide, N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-2-oxo-α-phenyl-3-[[(4-propylphenyl)sulfonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323196-98-1 HCAPLUS
CN Carbamic acid, [1-[(1S)-1-[[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-

trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]amino]carbonyl]-3-methylbutyl]-3-(1-methylethyl)-2-oxo-3-pyrrolidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323196-99-2 HCAPLUS
CN 1-Pyrrolidineacetamide, 3-amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-α-(2-methylpropyl)-2-oxo-, monohydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 323197-00-8 HCAPLUS
CN 1-Pyrrolidineacetamide, N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-α-(2-methylpropyl)-3-[(methylsulfonyl)amino]-2-oxo-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-01-9 HCAPLUS
CN 1-Pyrrolidineacetamide, N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-α-(2-methylpropyl)-2-oxo-3-[[(4-propylphenyl)sulfonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-02-0 HCAPLUS
CN Pyrazinecarboxamide, N-[(1S)-1-[[[1-[(1S)-1-(cyclohexylmethyl)-2-[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-butenyl]amino]-2-oxoethyl]-3-ethyl-2-oxo-3-pyrrolidinyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-03-1 HCAPLUS
CN Carbamic acid, [1-[(1S)-1-(cyclohexylmethyl)-2-[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]amino]-2-oxoethyl]-3-(1-methylethyl)-2-oxo-3-piperidinyl]-,

phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-04-2 HCAPLUS
CN Carbamic acid, [1-[(1S)-2-[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]amino]-2-oxo-1-phenylethyl]-3-(1-methylethyl)-2-oxo-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-05-3 HCAPLUS
CN 1-Piperidineacetamide, 3-amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-2-oxo-α-phenyl-, monohydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 323197-06-4 HCAPLUS
CN Carbamic acid, [1-[(1S)-2-[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]amino]-2-oxo-1-phenylethyl]-3-(1-methylethyl)-2-oxo-3-piperidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-07-5 HCAPLUS
CN 1-Piperidineacetamide, 3-(benzoylamino)-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-2-oxo-α-phenyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-08-6 HCAPLUS
CN 1-Piperidineacetamide, N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-3-[(methylsulfonyl)amino]-2-oxo-α-phenyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-09-7 HCAPLUS
CN 1-Piperidineacetamide, N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-3-[[(3-methylphenyl)sulfonyl]amino]-2-oxo-α-phenyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **85-46-1**, 1-Naphthylsulfonyl chloride **98-88-4**, Benzoyl chloride **103-71-9**, Phenyl isocyanate, reactions **106-95-6**, Allyl bromide, reactions **108-98-5**, Thiophenol, reactions **124-63-0**, Methanesulfonyl chloride **359-07-9** **460-37-7**, 3,3,3-Trifluoropropyl iodide **931-59-9**, Phenylsulfenyl chloride **1149-26-4 1623-93-4**, 4-Biphenylsulfonyl chloride **1730-25-2**, Allylmagnesium bromide **1899-93-0 3182-79-4 4333-56-6**, Cyclopropyl bromide **6009-07-0 13734-41-3 15028-39-4**, L-Phenylglycine methyl ester hydrochloride **17193-39-4** **18680-27-8 38329-34-9**, L-Phenylglycine hydrochloride **42918-86-5 76347-13-2 84110-32-7** **90084-27-8 119479-32-2 130653-09-7** **146949-07-7 323197-58-6 323197-73-5**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of lactam acylaminoalkaneboronates as inhibitors of hepatitis C virus NS3 protease)

RN 85-46-1 HCAPLUS
CN 1-Naphthalenesulfonyl chloride (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 98-88-4 HCAPLUS
CN Benzoyl chloride (8CI, 9CI) (CA INDEX NAME)



RN 103-71-9 HCAPLUS
CN Benzene, isocyanato- (9CI) (CA INDEX NAME)



RN 106-95-6 HCAPLUS
CN 1-Propene, 3-bromo- (9CI) (CA INDEX NAME)



RN 108-98-5 HCAPLUS
CN Benzenethiol (8CI, 9CI) (CA INDEX NAME)



RN 124-63-0 HCAPLUS
CN Methanesulfonyl chloride (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 359-07-9 HCAPLUS
CN Ethane, 2-bromo-1,1-difluoro- (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 460-37-7 HCAPLUS
CN Propane, 1,1,1-trifluoro-3-iodo- (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 931-59-9 HCAPLUS
CN Benzenesulfenyl chloride (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 1149-26-4 HCAPLUS
CN L-Valine, N-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 1623-93-4 HCAPLUS
CN [1,1'-Biphenyl]-4-sulfonyl chloride (9CI) (CA INDEX NAME)



RN 1730-25-2 HCAPLUS
CN Magnesium, bromo-2-propenyl- (9CI) (CA INDEX NAME)



RN 1899-93-0 HCAPLUS
CN Benzenesulfonyl chloride, 3-methyl- (9CI) (CA INDEX NAME)



RN 3182-79-4 HCAPLUS
CN Glycine, N-2-propenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 4333-56-6 HCAPLUS
CN Cyclopropane, bromo- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 6009-07-0 HCAPLUS
CN Disulfide, chloro phenyl (8CI, 9CI) (CA INDEX NAME)

PhS–S–Cl

RN 13734-41-3 HCAPLUS
CN L-Valine, N-[(1,1-dimethylethoxy)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 15028-39-4 HCAPLUS
CN Benzeneacetic acid, α-amino-, methyl ester, hydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 17193-39-4 HCAPLUS
CN Cyclohexanepropanoic acid, α-amino-, methyl ester, hydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 18680-27-8 HCAPLUS
CN Bicyclo[3.1.1]heptane-2,3-diol, 2,6,6-trimethyl-, (1S,2S,3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 38329-34-9 HCAPLUS
CN Benzeneacetic acid, α-amino-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 42918-86-5 HCAPLUS
CN Butanoic acid, 2-[[(phenylmethoxy)carbonyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 76347-13-2 HCAPLUS

CN 1,3,2-Dioxaborolane, 4,4,5,5-tetramethyl-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 84110-32-7 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole, 2-ethenylhexahydro-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 90084-27-8 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole, 2-[(1S)-1-chloro-2-(phenylmethoxy)ethyl]hexahydro-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 119479-32-2 HCAPLUS
CN 4-Pentenoic acid, 2-[[(1,1-dimethylethoxy)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 130653-09-7 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole, 2-(1-chloroethenyl)hexahydro-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)



RN 146949-07-7 HCAPLUS
CN Benzenesulfonyl chloride, 4-propyl- (9CI) (CA INDEX NAME)



RN 323197-58-6 HCAPLUS
CN L-Valine, N-(pyrazinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-73-5 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, hexahydro-3a,5,5-trimethyl-α-2-propenyl-, (αR,3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **66080-23-7P 66866-64-6P 70557-99-2P**
83622-42-8P 94242-86-1P 95656-94-3P
126689-01-8P 131357-48-7P 131433-93-7P
172096-96-7P 319009-74-0P 319009-76-2P
319009-78-4P 319009-80-8P 319009-82-0P
319009-90-0P 319009-92-2P 319009-94-4P
319009-96-6P 319009-98-8P 319010-99-6P
319011-02-4P 319011-08-0P 319011-10-4P
319011-16-0P 319011-18-2P 319011-22-8P
319011-25-1P 319011-27-3P 319011-29-5P
323197-10-0P 323197-11-1P 323197-12-2P
323197-13-3P 323197-14-4P 323197-15-5P
323197-16-6P 323197-17-7P 323197-18-8P
323197-19-9P 323197-20-2P 323197-21-3P
323197-22-4P 323197-23-5P 323197-24-6P
323197-25-7P 323197-26-8P 323197-27-9P
323197-28-0P 323197-29-1P 323197-30-4P
323197-31-5P 323197-32-6P 323197-33-7P
323197-34-8P 323197-35-9P 323197-36-0P
323197-37-1P 323197-38-2P 323197-39-3P
323197-40-6P 323197-41-7P 323197-42-8P
323197-43-9P 323197-44-0P 323197-45-1P
323197-46-2P 323197-47-3P 323197-48-4P
323197-74-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of lactam acylaminoalkaneboronates as inhibitors of hepatitis C virus NS3 protease)

RN 66080-23-7 HCAPLUS
CN 1,3,2-Dioxaborolane, 4,4,5,5-tetramethyl-2-[(phenylthio)methyl]- (9CI) (CA INDEX NAME)



RN 66866-64-6 HCAPLUS
CN 3-Oxazolidinecarboxylic acid, 4-(1-methylethyl)-5-oxo-, phenylmethyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 70557-99-2 HCAPLUS
CN 1,3,2-Dioxaborolane, 2-(iodomethyl)-4,4,5,5-tetramethyl- (9CI) (CA INDEX

NAME)



RN 83622-42-8 HCAPLUS
CN 1,3,2-Dioxaborolane, 2-(chloromethyl)-4,4,5,5-tetramethyl- (9CI) (CA INDEX NAME)



RN 94242-86-1 HCAPLUS
CN 1,3,2-Dioxaborolane, 2-(1-chloroethyl)-4,4,5,5-tetramethyl- (9CI) (CA INDEX NAME)



RN 95656-94-3 HCAPLUS
CN 3-Oxazolidinecarboxylic acid, 4-ethyl-5-oxo-, phenylmethyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 126689-01-8 HCAPLUS
CN 1,3,2-Dioxaborolane, 2-cyclopropyl-4,4,5,5-tetramethyl- (9CI) (CA INDEX NAME)



RN 131357-48-7 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole, 2-[(1S)-1-chloro-3-butenyl]hexahydro-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 131433-93-7 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole, hexahydro-3a,5,5-trimethyl-2-(2-propenyl)-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172096-96-7 HCAPLUS
CN 3-Oxazolidinecarboxylic acid, 4-(1-methylethyl)-5-oxo-, 1,1-dimethylethyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 319009-74-0 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, hexahydro-3a,5,5-

trimethyl-α-[1-(phenylmethoxy)ethyl]-, hydrochloride, (αR,3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 319009-76-2 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, hexahydro-3a,5,5-trimethyl-α-[(phenylmethoxy)methyl]-, hydrochloride, (αR,3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 319009-78-4 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, hexahydro-3a,5,5-trimethyl-α-[(phenylthio)methyl]-, hydrochloride, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 319009-80-8 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, hexahydro-3a,5,5-trimethyl-α-[(phenyldithio)methyl]-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 319009-82-0 HCAPLUS
CN 1,3,2-Dioxaborolane-2-methanamine, 4,4,5,5-tetramethyl-α-(3,3,3-trifluoropropyl)- (9CI) (CA INDEX NAME)



RN 319009-90-0 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, hexahydro-3a,5,5-trimethyl-α-2-propenyl-, hydrochloride, (αR,3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 319009-92-2 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, α-ethylhexahydro-3a,5,5-trimethyl-, hydrochloride, (αR,3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 319009-94-4 HCAPLUS
CN 1,3,2-Dioxaborolane-2-methanamine, α-cyclopropyl-4,4,5,5-tetramethyl- (9CI) (CA INDEX NAME)



RN 319009-96-6 HCAPLUS
CN 1,3,2-Dioxaborolane-2-methanamine, α-(2,2-difluoroethyl)-4,4,5,5-tetramethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 319009-98-8 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, α-ethenylhexahydro-3a,5,5-trimethyl-, hydrochloride, (αR,3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 319010-99-6 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole, 2-[(1S)-1-chloropropyl]hexahydro-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 319011-02-4 HCAPLUS
CN 1,3,2-Dioxaborolane, 2-(chlorocyclopropylmethyl)-4,4,5,5-tetramethyl- (9CI) (CA INDEX NAME)



RN 319011-08-0 HCAPLUS
CN 1,3,2-Dioxaborolane, 2-[3,3-difluoro-1-(phenylthio)propyl]-4,4,5,5-tetramethyl- (9CI) (CA INDEX NAME)



RN 319011-10-4 HCAPLUS
CN 1,3,2-Dioxaborolane, 2-(3,3-difluoro-1-iodopropyl)-4,4,5,5-tetramethyl- (9CI) (CA INDEX NAME)



RN 319011-16-0 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole, hexahydro-3a,5,5-trimethyl-2-[1-(phenylmethoxy)ethyl]-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 319011-18-2 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole, 2-[(1S)-1-chloro-2-(phenylmethoxy)propyl]hexahydro-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 319011-22-8 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole, 2-[1-chloro-2-(phenylthio)ethyl]hexahydro-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 319011-25-1 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole, 2-[1-chloro-2-(phenyldithio)ethyl]hexahydro-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 319011-27-3 HCAPLUS
CN 1,3,2-Dioxaborolane, 4,4,5,5-tetramethyl-2-[4,4,4-trifluoro-1-(phenylthio)butyl]- (9CI) (CA INDEX NAME)



RN 319011-29-5 HCAPLUS
CN 1,3,2-Dioxaborolane, 4,4,5,5-tetramethyl-2-(4,4,4-trifluoro-1-iodobutyl)-(9CI) (CA INDEX NAME)



RN 323197-10-0 HCAPLUS
CN 3-Oxazolidinecarboxylic acid, 4-(1-methylethyl)-5-oxo-4-(2-propenyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 323197-11-1 HCAPLUS
CN 4-Pentenoic acid, 2-(1-methylethyl)-2-[[(phenylmethoxy)carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 323197-12-2 HCAPLUS
CN Valine, 2-(2-oxoethyl)-N-[(phenylmethoxy)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 323197-13-3 HCAPLUS
CN 1-Pyrrolidineacetic acid, α-(cyclohexylmethyl)-3-(1-methylethyl)-2-oxo-3-[[(phenylmethoxy)carbonyl]amino]-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-14-4 HCAPLUS
CN 1-Pyrrolidineacetic acid, 3-amino-α-(cyclohexylmethyl)-3-(1-methylethyl)-2-oxo-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-15-5 HCAPLUS
CN 1-Pyrrolidineacetic acid, α-(cyclohexylmethyl)-3-(1-methylethyl)-3-[[(2S)-3-methyl-1-oxo-2-[(pyrazinylcarbonyl)amino]butyl]amino]-2-oxo-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-16-6 HCAPLUS
CN 1-Pyrrolidineacetic acid, α-(cyclohexylmethyl)-3-(1-methylethyl)-3-[[(2S)-3-methyl-1-oxo-2-[(pyrazinylcarbonyl)amino]butyl]amino]-2-oxo-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-17-7 HCAPLUS
CN Norvaline, 5-hydroxy-2-(1-methylethyl)-N-[(phenylmethoxy)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 323197-18-8 HCAPLUS
CN Norvaline, 2-(1-methylethyl)-5-oxo-N-[(phenylmethoxy)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 323197-19-9 HCAPLUS
CN Cyclohexanepropanoic acid, α-[[4-(methoxycarbonyl)-5-methyl-4-[[(phenylmethoxy)carbonyl]amino]hexyl]amino]-, methyl ester, (αS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-20-2 HCAPLUS
CN 1-Piperidineacetic acid, α-(cyclohexylmethyl)-3-(1-methylethyl)-2-oxo-3-[[(phenylmethoxy)carbonyl]amino]-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-21-3 HCAPLUS
CN 1-Piperidineacetic acid, 3-amino-α-(cyclohexylmethyl)-3-(1-methylethyl)-2-oxo-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-22-4 HCAPLUS
CN 1-Piperidineacetic acid, α-(cyclohexylmethyl)-3-(1-methylethyl)-3-[[(2S)-3-methyl-1-oxo-2-[(pyrazinylcarbonyl)amino]butyl]amino]-2-oxo-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-23-5 HCAPLUS
CN 1-Piperidineacetic acid, α-(cyclohexylmethyl)-3-(1-methylethyl)-3-[[(2S)-3-methyl-1-oxo-2-[(pyrazinylcarbonyl)amino]butyl]amino]-2-oxo-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-24-6 HCAPLUS
CN Glycine, 4,5-didehydro-N-[(1,1-dimethylethoxy)carbonyl]norvalyl-N-2-propenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 323197-25-7 HCAPLUS
CN 1H-Azepine-1-acetic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2,3,4,7-tetrahydro-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 323197-26-8 HCAPLUS
CN 1H-Azepine-1-acetic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2,3,4,7-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)



RN 323197-27-9 HCAPLUS
CN Carbamic acid, [1-[2-[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]amino]-2-oxoethyl]hexahydro-2-oxo-1H-azepin-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-28-0 HCAPLUS
CN 1H-Azepine-1-acetamide, 3-amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]hexahydro-2-

oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-29-1 HCAPLUS
CN 1-Pyrrolidineacetic acid, α-(cyclohexylmethyl)-3-(1-methylethyl)-2-oxo-3-[[(phenylmethoxy)carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-30-4 HCAPLUS
CN Carbamic acid, [1-[(1S)-1-(cyclohexylmethyl)-2-[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]amino]-2-oxoethyl]-3-(1-methylethyl)-2-oxo-3-pyrrolidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-31-5 HCAPLUS
CN 1-Pyrrolidineacetic acid, 3-(1-methylethyl)-2-oxo-α-phenyl-3-[[(phenylmethoxy)carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-32-6 HCAPLUS
CN 1-Pyrrolidineacetic acid, 3-(1-methylethyl)-α-(2-methylpropyl)-2-oxo-3-[[(phenylmethoxy)carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-33-7 HCAPLUS
CN 3-Oxazolidinecarboxylic acid, 4-ethyl-5-oxo-4-(2-propenyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 323197-34-8 HCAPLUS
CN 4-Pentenoic acid, 2-ethyl-2-[[(phenylmethoxy)carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 323197-35-9 HCAPLUS
CN Butanoic acid, 2-ethyl-4-oxo-2-[[(phenylmethoxy)carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 323197-36-0 HCAPLUS
CN 1-Pyrrolidineacetic acid, α-(cyclohexylmethyl)-3-ethyl-2-oxo-3-[[(phenylmethoxy)carbonyl]amino]-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-37-1 HCAPLUS
CN 1-Pyrrolidineacetic acid, 3-amino-α-(cyclohexylmethyl)-3-ethyl-2-oxo-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-38-2 HCAPLUS
CN 1-Pyrrolidineacetic acid, α-(cyclohexylmethyl)-3-ethyl-3-[[(2S)-3-methyl-1-oxo-2-[(pyrazinylcarbonyl)amino]butyl]amino]-2-oxo-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-39-3 HCAPLUS
CN 1-Pyrrolidineacetic acid, α-(cyclohexylmethyl)-3-ethyl-3-[[(2S)-3-methyl-1-oxo-2-[(pyrazinylcarbonyl)amino]butyl]amino]-2-oxo-, (αS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-40-6 HCAPLUS
CN 3-Oxazolidinecarboxylic acid, 4-(1-methylethyl)-5-oxo-4-(2-propenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 323197-41-7 HCAPLUS
CN 4-Pentenoic acid, 2-[[(1,1-dimethylethoxy)carbonyl]amino]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 323197-42-8 HCAPLUS
CN 4-Pentenoic acid, 2-[[(1,1-dimethylethoxy)carbonyl]amino]-2-(1-methylethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 323197-43-9 HCAPLUS
CN Norvaline, N-[(1,1-dimethylethoxy)carbonyl]-5-hydroxy-2-(1-methylethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 323197-44-0 HCAPLUS
CN Norvaline, N-[(1,1-dimethylethoxy)carbonyl]-2-(1-methylethyl)-5-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 323197-45-1 HCAPLUS
CN Benzeneacetic acid, α-[[4-[[(1,1-dimethylethoxy)carbonyl]amino]-5-methyl-4-[(phenylmethoxy)carbonyl]hexyl]amino]-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-46-2 HCAPLUS
CN Benzeneacetic acid, α-[[4-carboxy-4-[[(1,1-dimethylethoxy)carbonyl]amino]-5-methylhexyl]amino]-, monomethyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-47-3 HCAPLUS
CN 1-Piperidineacetic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-3-(1-methylethyl)-2-oxo-α-phenyl-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-48-4 HCAPLUS
CN 1-Piperidineacetic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-3-(1-methylethyl)-2-oxo-α-phenyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-74-6 HCAPLUS
CN 1-Pyrrolidineacetic acid, 3-(1-methylethyl)-2-oxo-α-phenyl-3-[[(phenylmethoxy)carbonyl]amino]-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **483387-26-4 483387-27-5 483387-28-6**
483387-29-7
RL: PRP (Properties)
(unclaimed protein sequence; preparation of lactam acylaminoalkaneboronates as inhibitors of hepatitis C virus NS3 protease.)
RN 483387-26-4 HCAPLUS
CN Peptide, (Asp-Glu-Xaa-Glu-Xaa-Cys) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 483387-27-5 HCAPLUS
CN Peptide, (Asp-Xaa-Ile-Val-Pro-Cys) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 483387-28-6 HCAPLUS
CN Peptide, (Asp-Glu-Val-Val-Pro-Xaa) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 483387-29-7 HCAPLUS
CN Peptide, (Asp-Glu-Asp-Glu-Glu-Xaa-Ala-Ser-Lys) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **204765-53-7 438493-18-6 483340-48-3**
483340-49-4
RL: PRP (Properties)
(unclaimed sequence; preparation of lactam acylaminoalkaneboronates as inhibitors of hepatitis C virus NS3 protease.)
RN 204765-53-7 HCAPLUS
CN L-Lysine, L-lysyl-L-lysylglycyl-L-seryl-L-valyl-L-valyl-L-isoleucyl-L-valylglycyl-L-arginyl-L-isoleucyl-L-valyl-L-leucyl-L-serylglycyl-L-lysyl-L-prolyl-L-alanyl-L-isoleucyl-L-isoleucyl-L-prolyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-C



PAGE 2-D



RN 438493-18-6 HCAPLUS
CN L-Histidine, L-methionyl-L-arginylglycyl-L-seryl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-methionylglycyl-L-alanyl-L-glutaminyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 483340-48-3 HCAPLUS
CN L-Histidine, L-methionylglycyl-L-alanyl-L-glutaminyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 483340-49-4 HCAPLUS
CN L-Cysteine, L-α-aspartyl-L-α-glutamyl-L-α-glutamyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:767330 HCAPLUS
DOCUMENT NUMBER: 138:221813
TITLE: P1 Phenethyl peptide boronic acid inhibitors of HCV NS3 protease
AUTHOR(S): **Priestley, E. Scott**; De Lucca, Indawati; Ghavimi, Bahman; Erickson-Viitanen, Susan; **Decicco, Carl P.**
CORPORATE SOURCE: Experimental Station, Bristol-Myers Squibb Pharmaceutical Research Institute, Wilmington, DE, 19880-0500, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2002), 12(21), 3199-3202
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A series of peptide boronic acids containing extended, hydrophobic P1 residues was prepared to probe the shallow, hydrophobic S1 region of HCV NS3 protease. The p-trifluoromethylphenethyl P1 substituent was identified as

optimal with respect to inhibitor potency for NS3 and selectivity against elastase and chymotrypsin.

IT **9004-06-2**, Elastase **9004-07-3**, Chymotrypsin
149885-80-3, Ns3 protease
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of P1 phenethyl peptide boronic acid inhibitors of HCV NS3 protease)

RN 9004-06-2 HCAPLUS
CN Elastase (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9004-07-3 HCAPLUS
CN Chymotrypsin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 149885-80-3 HCAPLUS
CN Proteinase, polyprotein-processing, NS3 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **500763-17-7P 500763-19-9P 500763-21-3P**
500763-23-5P 500763-25-7P 500763-27-9P
500763-29-1P 500763-31-5P 500763-33-7P
500763-35-9P 500763-37-1P 500763-39-3P
500763-42-8P 500763-44-0P 500763-46-2P
500763-48-4P 500763-50-8P 500763-52-0P
500763-53-1P 500763-55-3P 500763-57-5P
500763-59-7P 500763-61-1P 500763-63-3P
500763-65-5P 500763-67-7P 500763-69-9P
500763-71-3P 500763-73-5P 500763-74-6P
500763-75-7P 500763-76-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of P1 phenethyl peptide boronic acid inhibitors of HCV NS3 protease)

RN 500763-17-7 HCAPLUS
CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 500763-19-9 HCAPLUS

CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[(1R)-1-[(3aS,4S,6S,7aR)-3a-butylhexahydro-5,5-dimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 500763-21-3 HCAPLUS
CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-5,5-dimethyl-3a-pentyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 500763-23-5 HCAPLUS
CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[(1R)-1-[(3aS,4S,6S,7aR)-3a-hexylhexahydro-5,5-dimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 500763-25-7 HCAPLUS
CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-5,5-dimethyl-3a-(2-methylpropyl)-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 500763-27-9 HCAPLUS
CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-5,5-dimethyl-3a-(3-methylbutyl)-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 500763-29-1 HCAPLUS
CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-5,5-dimethyl-3a-(4-methylpentyl)-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 500763-31-5 HCAPLUS
CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[(1R)-1-[(3aR,4S,6S,7aR)-hexahydro-5,5-dimethyl-3a-phenyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 500763-33-7 HCAPLUS
CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-5,5-dimethyl-3a-(phenylmethyl)-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 500763-35-9 HCAPLUS
CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-5,5-dimethyl-3a-(2-phenylethyl)-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 500763-37-1 HCAPLUS
CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-5,5-dimethyl-3a-(3-phenylpropyl)-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 500763-39-3 HCAPLUS
CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-5,5-dimethyl-3a-(4-phenylbutyl)-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 500763-42-8 HCAPLUS
CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-5,5-dimethyl-3a-[2-(2-methylphenyl)ethyl]-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 500763-44-0 HCAPLUS
CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-5,5-dimethyl-3a-[2-(3-methylphenyl)ethyl]-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 500763-46-2 HCAPLUS
CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-5,5-dimethyl-3a-[2-(4-methylphenyl)ethyl]-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

Me

RN 500763-48-4 HCAPLUS
CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[(1R)-1-[(3aS,4S,6S,7aR)-3a-[2-(2,4-dimethylphenyl)ethyl]hexahydro-5,5-dimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

Me

RN 500763-50-8 HCAPLUS
CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[(1R)-1-[(3aS,4S,6S,7aR)-3a-[2-(2,5-dimethylphenyl)ethyl]hexahydro-5,5-dimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 500763-52-0 HCAPLUS
CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[(1R)-1-[(3aS,4S,6S,7aR)-3a-[2-(2-fluorophenyl)ethyl]hexahydro-5,5-dimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 500763-53-1 HCAPLUS
CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[(1R)-1-[(3aS,4S,6S,7aR)-3a-[2-(3-fluorophenyl)ethyl]hexahydro-5,5-

dimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 500763-55-3 HCAPLUS
CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[(1R)-1-[(3aS,4S,6S,7aR)-3a-[2-(4-fluorophenyl)ethyl]hexahydro-5,5-dimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 500763-57-5 HCAPLUS
CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[(1R)-1-[(3aS,4S,6S,7aR)-3a-[2-(2,6-difluorophenyl)ethyl]hexahydro-5,5-dimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 500763-59-7 HCAPLUS
CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-5,5-dimethyl-3a-[2-[3-(trifluoromethyl)phenyl]ethyl]-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 500763-61-1 HCAPLUS
CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-5,5-dimethyl-3a-[2-[4-

(trifluoromethyl)phenyl]ethyl]-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 500763-63-3 HCAPLUS

CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[(1R)-1-[(3aS,4S,6S,7aR)-3a-[2-(4-chlorophenyl)ethyl]hexahydro-5,5-dimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 500763-65-5 HCAPLUS
CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[(1R)-1-[(3aS,4S,6S,7aR)-3a-[2-(4-bromophenyl)ethyl]hexahydro-5,5-dimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 500763-67-7 HCAPLUS
CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[(1R)-1-[(3aS,4S,6S,7aR)-3a-(2-[1,1'-biphenyl]-4-ylethyl)hexahydro-5,5-dimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 500763-69-9 HCAPLUS
CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-5,5-dimethyl-3a-[2-[4-(1-methylethyl)phenyl]ethyl]-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 500763-71-3 HCAPLUS
CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[(1R)-1-[(3aS,4S,6S,7aR)-3a-[2-(4-cyclohexylphenyl)ethyl]hexahydro-5,5-dimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 500763-73-5 HCAPLUS
CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[(1R)-1-[(3aS,4S,6S,7aR)-3a-[2-[4-(1,1-dimethylethyl)phenyl]ethyl]hexahydro-5,5-dimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 500763-74-6 HCAPLUS
CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a-[2-(4-hydroxyphenyl)ethyl]-5,5-dimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 500763-75-7 HCAPLUS
CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a-[2-(4-methoxyphenyl)ethyl]-5,5-dimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 500763-76-8 HCAPLUS
CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-5,5-dimethyl-3a-[2-(4-phenoxyphenyl)ethyl]-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

IT **98-80-6**, Phenylboronic acid **100-58-3**, Phenylmagnesium bromide **100-80-1**, 3 Methylstyrene **350-51-6**, 3 Fluorostyrene **394-46-7**, 2 Fluorostyrene **402-24-4**, 3 Trifluoromethylstyrene **402-50-6**, 4 Trifluoromethylstyrene **405-99-2**, 4 Fluorostyrene **611-15-4**, 2 Methylstyrene **622-97-9**, 4 Methylstyrene **637-69-4**, 4 Methoxystyrene **693-03-8**, Butylmagnesium bromide **693-25-4**, Pentylmagnesium bromide **925-90-6**, Ethylmagnesium bromide **926-62-5**, Isobutylmagnesium bromide **1073-67-2**, 4 Chlorostyrene **1462-75-5 1589-82-8**, Benzylmagnesium bromide **1746-23-2**, 4 tert Butylstyrene **2039-82-9**, 4 Bromostyrene **2039-89-6**, 2 5 Dimethylstyrene **2055-40-5**, 4 Isopropylstyrene **2146-67-0**, Dichloromethyllithium **2234-20-0**, 2 4 Dimethylstyrene **2350-89-2**, 4 Phenylstyrene **2628-17-3**, 4 Hydroxystyrene **3277-89-2**, Phenethylmagnesium bromide **3761-92-0**, Hexylmagnesium bromide **4548-78-1**, Isopentylmagnesium bromide **4973-29-9**, 4 Phenoxystyrene **5419-55-6**, Triisopropyl borate **7429-94-9** , 4-Methylpentylmagnesium bromide **13020-34-3**, 4 Cyclohexylstyrene **18680-27-8 27152-04-1** **207226-37-7**, 2 6 Difluorostyrene **274918-51-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of P1 phenethyl peptide boronic acid inhibitors of HCV NS3 protease)

RN 98-80-6 HCAPLUS
CN Boronic acid, phenyl- (9CI) (CA INDEX NAME)



RN 100-58-3 HCAPLUS
CN Magnesium, bromophenyl- (8CI, 9CI) (CA INDEX NAME)



RN 100-80-1 HCAPLUS
CN Benzene, 1-ethenyl-3-methyl- (9CI) (CA INDEX NAME)



RN 350-51-6 HCAPLUS
CN Benzene, 1-ethenyl-3-fluoro- (9CI) (CA INDEX NAME)



RN 394-46-7 HCAPLUS
CN Benzene, 1-ethenyl-2-fluoro- (9CI) (CA INDEX NAME)



RN 402-24-4 HCAPLUS
CN Benzene, 1-ethenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 402-50-6 HCAPLUS
CN Benzene, 1-ethenyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 405-99-2 HCAPLUS
CN Benzene, 1-ethenyl-4-fluoro- (9CI) (CA INDEX NAME)



RN 611-15-4 HCAPLUS
CN Benzene, 1-ethenyl-2-methyl- (9CI) (CA INDEX NAME)



RN 622-97-9 HCAPLUS
CN Benzene, 1-ethenyl-4-methyl- (9CI) (CA INDEX NAME)



RN 637-69-4 HCAPLUS
CN Benzene, 1-ethenyl-4-methoxy- (9CI) (CA INDEX NAME)



RN 693-03-8 HCAPLUS
CN Magnesium, bromobutyl- (8CI, 9CI) (CA INDEX NAME)



RN 693-25-4 HCAPLUS
CN Magnesium, bromopentyl- (7CI, 8CI, 9CI) (CA INDEX NAME)

Me— $(CH_2)_4$ —Mg— Br

RN 925-90-6 HCAPLUS
CN Magnesium, bromoethyl- (8CI, 9CI) (CA INDEX NAME)

H_3C — CH_2 — Mg — Br

RN 926-62-5 HCAPLUS
CN Magnesium, bromo(2-methylpropyl)- (9CI) (CA INDEX NAME)

i-Bu— Mg— Br

RN 1073-67-2 HCAPLUS
CN Benzene, 1-chloro-4-ethenyl- (9CI) (CA INDEX NAME)



RN 1462-75-5 HCAPLUS
CN Magnesium, bromo(3-phenylpropyl)- (8CI, 9CI) (CA INDEX NAME)

Ph— $(CH_2)_3$ — Mg— Br

RN 1589-82-8 HCAPLUS
CN Magnesium, bromo(phenylmethyl)- (9CI) (CA INDEX NAME)

Ph— CH_2 Mg Br

RN 1746-23-2 HCAPLUS
CN Benzene, 1-(1,1-dimethylethyl)-4-ethenyl- (9CI) (CA INDEX NAME)



RN 2039-82-9 HCAPLUS
CN Benzene, 1-bromo-4-ethenyl- (9CI) (CA INDEX NAME)



RN 2039-89-6 HCAPLUS
CN Benzene, 2-ethenyl-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 2055-40-5 HCAPLUS
CN Benzene, 1-ethenyl-4-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 2146-67-0 HCAPLUS
CN Lithium, (dichloromethyl)- (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 2234-20-0 HCAPLUS
CN Benzene, 1-ethenyl-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 2350-89-2 HCAPLUS
CN 1,1'-Biphenyl, 4-ethenyl- (9CI) (CA INDEX NAME)



RN 2628-17-3 HCAPLUS
CN Phenol, 4-ethenyl- (9CI) (CA INDEX NAME)



RN 3277-89-2 HCAPLUS
CN Magnesium, bromo(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 3761-92-0 HCAPLUS
CN Magnesium, bromohexyl- (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 4548-78-1 HCAPLUS
CN Magnesium, bromo(3-methylbutyl)- (9CI) (CA INDEX NAME)



RN 4973-29-9 HCAPLUS
CN Benzene, 1-ethenyl-4-phenoxy- (9CI) (CA INDEX NAME)



RN 5419-55-6 HCAPLUS
CN Boric acid (H3BO3), tris(1-methylethyl) ester (9CI) (CA INDEX NAME)



RN 7429-94-9 HCAPLUS

CN Magnesium, bromo(4-methylpentyl)- (9CI) (CA INDEX NAME)

RN 13020-34-3 HCAPLUS
CN Benzene, 1-cyclohexyl-4-ethenyl- (9CI) (CA INDEX NAME)

RN 18680-27-8 HCAPLUS
CN Bicyclo[3.1.1]heptane-2,3-diol, 2,6,6-trimethyl-, (1S,2S,3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 27152-04-1 HCAPLUS
CN Magnesium, bromo(4-phenylbutyl)- (8CI, 9CI) (CA INDEX NAME)



RN 207226-37-7 HCAPLUS
CN Benzene, 2-ethenyl-1,3-difluoro- (9CI) (CA INDEX NAME)



RN 274918-51-3 HCAPLUS
CN L-Proline, N-[(1,1-dimethylethoxy)carbonyl]-L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:78359 HCAPLUS
DOCUMENT NUMBER: 134:147855
TITLE: Preparation of lactam acylaminoalkaneboronates as inhibitors of hepatitis C virus NS3 protease.
INVENTOR(S): **Priestley, E. Scott; Decicco, Carl P.**
PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA
SOURCE: PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001007407	A1	20010201	WO 2000-US20189	20000726
W: AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1206449	A1	20020522	EP 2000-950642	20000726
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				

PRIORITY APPLN. INFO.: US 1999-145631P P 19990726
WO 2000-US20189 W 20000726
OTHER SOURCE(S): MARPAT 134:147855
GI



I

AB Title compds. [I; X = B(OH)2, BYY1, COCONHR1a; Y1, Y2 = OH, F, amino, alkoxy; BY1Y2 = atoms to form a cyclic boron ester, amide, or amide-ester containing 2-20 C atoms and optionally 1-3 N, O, or S atoms; R1, R1a = (substituted) alkyl, alkenyl, alkynyl, cycloalkyl; R2 = H; R1R2C = cycloalkyl; R3 = (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, Ph, naphthyl, heteroaryl; R4 = H, (substituted) alkyl, Ph, PhCH2, PhCH2CH2; R5 = H, QR5a; Q = chain of 0-3 amino acids; R5a = SOR6, SO2R7, COR6, CO2R8; R6 = (substituted) alkyl, Ph, naphthyl, PhCH2, heteroaryl; R7 = H, alkyl; R8 = alkyl, PhCH2, cycloalkylmethyl; Q = (CH2)1-3], were prepared Thus, (1R)-1-[[(2S)-3-cyclohexyl-2-[3-isopropyl-3-[[(2S)-3-methyl-2-[(2-pyrazinylcarbonyl)amino]butanoyl]amino]-2-oxo-1-pyrrolidinyl]propanoyl]amino]-3-butenylboronic acid (+)-pinanediol ester was prepared by solution phase chemical A number of I inhibited hepatitis C virus NS3 protease with Ki<60 μM.

IT **149885-80-3**

RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)
(inhibitors; preparation of lactam acylaminoalkaneboronates as inhibitors of hepatitis C virus NS3 protease)

RN 149885-80-3 HCAPLUS

CN Proteinase, polyprotein-processing, NS3 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **323196-84-5P 323196-85-6P 323196-86-7P**
323196-87-8P 323196-88-9P 323196-89-0P
323196-90-3P 323196-91-4P 323196-92-5P
323196-93-6P 323196-94-7P 323196-95-8P
323196-96-9P 323196-97-0P 323196-98-1P
323196-99-2P 323197-00-8P 323197-01-9P
323197-02-0P 323197-03-1P 323197-04-2P
323197-05-3P 323197-06-4P 323197-07-5P
323197-08-6P 323197-09-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of lactam acylaminoalkaneboronates as inhibitors of hepatitis C virus NS3 protease)

RN 323196-84-5 HCAPLUS

CN Pyrazinecarboxamide, N-[(1S)-1-[[[1-[(1S)-1-(cyclohexylmethyl)-2-[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-butenyl]amino]-2-oxoethyl]-3-(1-methylethyl)-2-oxo-3-pyrrolidinyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323196-85-6 HCAPLUS
CN Pyrazinecarboxamide, N-[(1S)-1-[[[1-[(1S)-1-(cyclohexylmethyl)-2-[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-butenyl]amino]-2-oxoethyl]-3-(1-methylethyl)-2-oxo-3-piperidinyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323196-86-7 HCAPLUS
CN 1H-Azepine-1-acetamide, N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]hexahydro-3-[(methylsulfonyl)amino]-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323196-87-8 HCAPLUS
CN 1-Pyrrolidineacetamide, 3-amino-α-(cyclohexylmethyl)-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-2-oxo-, monohydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 323196-88-9 HCAPLUS
CN 1-Pyrrolidineacetamide, 3-[([1,1'-biphenyl]-4-ylsulfonyl)amino]-α-(cyclohexylmethyl)-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-2-oxo-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323196-89-0 HCAPLUS
CN 1-Pyrrolidineacetamide, α-(cyclohexylmethyl)-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-2-oxo-3-[[(4-propylphenyl)sulfonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323196-90-3 HCAPLUS
CN 1-Pyrrolidineacetamide, α-(cyclohexylmethyl)-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-3-[(1-naphthalenylsulfonyl)amino]-2-oxo-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323196-91-4 HCAPLUS
CN 1-Pyrrolidineacetamide, α-(cyclohexylmethyl)-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-2-oxo-3-[[(phenylamino)carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323196-92-5 HCAPLUS
CN 1-Pyrrolidineacetamide, α-(cyclohexylmethyl)-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-3-[[(3-methylphenyl)sulfonyl]amino]-2-oxo-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323196-93-6 HCAPLUS
CN Boronic acid, [(1R)-1-[[(2S)-3-cyclohexyl-2-[3-(1-methylethyl)-3-[[(3-methylphenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323196-94-7 HCAPLUS
CN Carbamic acid, [1-[(1S)-2-[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]amino]-2-oxo-1-phenylethyl]-3-(1-methylethyl)-2-oxo-3-pyrrolidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323196-95-8 HCAPLUS
CN 1-Pyrrolidineacetamide, 3-amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-2-oxo-α-phenyl-, monohydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 323196-96-9 HCAPLUS
CN 1-Pyrrolidineacetamide, N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-3-[(methylsulfonyl)amino]-2-oxo-α-phenyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323196-97-0 HCAPLUS
CN 1-Pyrrolidineacetamide, N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-2-oxo-α-phenyl-3-[[(4-propylphenyl)sulfonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323196-98-1 HCAPLUS
CN Carbamic acid, [1-[(1S)-1-[[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-

trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]amino]carbonyl]-3-methylbutyl]-3-(1-methylethyl)-2-oxo-3-pyrrolidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323196-99-2 HCAPLUS
CN 1-Pyrrolidineacetamide, 3-amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-α-(2-methylpropyl)-2-oxo-, monohydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 323197-00-8 HCAPLUS
CN 1-Pyrrolidineacetamide, N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-α-(2-methylpropyl)-3-[(methylsulfonyl)amino]-2-oxo-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-01-9 HCAPLUS
CN 1-Pyrrolidineacetamide, N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-α-(2-methylpropyl)-2-oxo-3-[[(4-propylphenyl)sulfonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-02-0 HCAPLUS
CN Pyrazinecarboxamide, N-[(1S)-1-[[[1-[(1S)-1-(cyclohexylmethyl)-2-[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-butenyl]amino]-2-oxoethyl]-3-ethyl-2-oxo-3-pyrrolidinyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-03-1 HCAPLUS
CN Carbamic acid, [1-[(1S)-1-(cyclohexylmethyl)-2-[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]amino]-2-oxoethyl]-3-(1-methylethyl)-2-oxo-3-piperidinyl]-,

phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-04-2 HCAPLUS
CN Carbamic acid, [1-[(1S)-2-[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]amino]-2-oxo-1-phenylethyl]-3-(1-methylethyl)-2-oxo-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-05-3 HCAPLUS
CN 1-Piperidineacetamide, 3-amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-2-oxo-α-phenyl-, monohydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 323197-06-4 HCAPLUS
CN Carbamic acid, [1-[(1S)-2-[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]amino]-2-oxo-1-phenylethyl]-3-(1-methylethyl)-2-oxo-3-piperidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-07-5 HCAPLUS
CN 1-Piperidineacetamide, 3-(benzoylamino)-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-2-oxo-α-phenyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-08-6 HCAPLUS
CN 1-Piperidineacetamide, N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-3-[(methylsulfonyl)amino]-2-oxo-α-phenyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-09-7 HCAPLUS
CN 1-Piperidineacetamide, N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-(1-methylethyl)-3-[[(3-methylphenyl)sulfonyl]amino]-2-oxo-α-phenyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **85-46-1**, 1-Naphthylsulfonyl chloride **98-88-4**, Benzoyl chloride **103-71-9**, Phenyl isocyanate, reactions **106-95-6**, Allyl bromide, reactions **108-98-5**, Thiophenol, reactions **124-63-0**, Methanesulfonyl chloride **359-07-9** **460-37-7**, 3,3,3-Trifluoropropyl iodide **931-59-9**, Phenylsulfenyl chloride **1149-26-4** **1623-93-4**, 4-Biphenylsulfonyl chloride **1730-25-2**, Allylmagnesium bromide **1899-93-0** **3182-79-4** **4333-56-6**, Cyclopropyl bromide **6009-07-0** **13734-41-3** **15028-39-4**, L-Phenylglycine methyl ester hydrochloride **17193-39-4** **18680-27-8** **38329-34-9**, L-Phenylglycine hydrochloride **42918-86-5** **76347-13-2** **84110-32-7** **90084-27-8** **119479-32-2** **130653-09-7** **146949-07-7** **323197-58-6** **323197-73-5**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of lactam acylaminoalkaneboronates as inhibitors of hepatitis C virus NS3 protease)

RN 85-46-1 HCAPLUS
CN 1-Naphthalenesulfonyl chloride (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 98-88-4 HCAPLUS
CN Benzoyl chloride (8CI, 9CI) (CA INDEX NAME)



RN 103-71-9 HCAPLUS
CN Benzene, isocyanato- (9CI) (CA INDEX NAME)



RN 106-95-6 HCAPLUS
CN 1-Propene, 3-bromo- (9CI) (CA INDEX NAME)



RN 108-98-5 HCAPLUS
CN Benzenethiol (8CI, 9CI) (CA INDEX NAME)



RN 124-63-0 HCAPLUS
CN Methanesulfonyl chloride (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 359-07-9 HCAPLUS
CN Ethane, 2-bromo-1,1-difluoro- (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 460-37-7 HCAPLUS
CN Propane, 1,1,1-trifluoro-3-iodo- (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 931-59-9 HCAPLUS
CN Benzenesulfenyl chloride (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

RN 1149-26-4 HCAPLUS
CN L-Valine, N-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 1623-93-4 HCAPLUS
CN [1,1'-Biphenyl]-4-sulfonyl chloride (9CI) (CA INDEX NAME)



RN 1730-25-2 HCAPLUS
CN Magnesium, bromo-2-propenyl- (9CI) (CA INDEX NAME)



RN 1899-93-0 HCAPLUS
CN Benzenesulfonyl chloride, 3-methyl- (9CI) (CA INDEX NAME)



RN 3182-79-4 HCAPLUS
CN Glycine, N-2-propenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 4333-56-6 HCAPLUS
CN Cyclopropane, bromo- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 6009-07-0 HCAPLUS
CN Disulfide, chloro phenyl (8CI, 9CI) (CA INDEX NAME)



RN 13734-41-3 HCAPLUS
CN L-Valine, N-[(1,1-dimethylethoxy)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 15028-39-4 HCAPLUS
CN Benzeneacetic acid, α-amino-, methyl ester, hydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 17193-39-4 HCAPLUS
CN Cyclohexanepropanoic acid, α-amino-, methyl ester, hydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 18680-27-8 HCAPLUS
CN Bicyclo[3.1.1]heptane-2,3-diol, 2,6,6-trimethyl-, (1S,2S,3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 38329-34-9 HCAPLUS
CN Benzeneacetic acid, α-amino-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 42918-86-5 HCAPLUS
CN Butanoic acid, 2-[[(phenylmethoxy)carbonyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 76347-13-2 HCAPLUS

CN 1,3,2-Dioxaborolane, 4,4,5,5-tetramethyl-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 84110-32-7 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole, 2-ethenylhexahydro-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 90084-27-8 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole, 2-[(1S)-1-chloro-2-(phenylmethoxy)ethyl]hexahydro-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 119479-32-2 HCAPLUS
CN 4-Pentenoic acid, 2-[[(1,1-dimethylethoxy)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 130653-09-7 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole, 2-(1-chloroethenyl)hexahydro-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)



RN 146949-07-7 HCAPLUS
CN Benzenesulfonyl chloride, 4-propyl- (9CI) (CA INDEX NAME)



RN 323197-58-6 HCAPLUS
CN L-Valine, N-(pyrazinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-73-5 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, hexahydro-3a,5,5-trimethyl-α-2-propenyl-, (αR,3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **66080-23-7P 66866-64-6P 70557-99-2P**
83622-42-8P 94242-86-1P 95656-94-3P
126689-01-8P 131357-48-7P 131433-93-7P
172096-96-7P 319009-74-0P 319009-76-2P
319009-78-4P 319009-80-8P 319009-82-0P
319009-90-0P 319009-92-2P 319009-94-4P
319009-96-6P 319009-98-8P 319010-99-6P
319011-02-4P 319011-08-0P 319011-10-4P
319011-16-0P 319011-18-2P 319011-22-8P
319011-25-1P 319011-27-3P 319011-29-5P
323197-10-0P 323197-11-1P 323197-12-2P
323197-13-3P 323197-14-4P 323197-15-5P
323197-16-6P 323197-17-7P 323197-18-8P
323197-19-9P 323197-20-2P 323197-21-3P
323197-22-4P 323197-23-5P 323197-24-6P
323197-25-7P 323197-26-8P 323197-27-9P
323197-28-0P 323197-29-1P 323197-30-4P
323197-31-5P 323197-32-6P 323197-33-7P
323197-34-8P 323197-35-9P 323197-36-0P
323197-37-1P 323197-38-2P 323197-39-3P
323197-40-6P 323197-41-7P 323197-42-8P
323197-43-9P 323197-44-0P 323197-45-1P
323197-46-2P 323197-47-3P 323197-48-4P
323197-74-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of lactam acylaminoalkaneboronates as inhibitors of hepatitis C virus NS3 protease)

RN 66080-23-7 HCAPLUS
CN 1,3,2-Dioxaborolane, 4,4,5,5-tetramethyl-2-[(phenylthio)methyl]- (9CI) (CA INDEX NAME)



RN 66866-64-6 HCAPLUS
CN 3-Oxazolidinecarboxylic acid, 4-(1-methylethyl)-5-oxo-, phenylmethyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 70557-99-2 HCAPLUS
CN 1,3,2-Dioxaborolane, 2-(iodomethyl)-4,4,5,5-tetramethyl- (9CI) (CA INDEX

NAME)



RN 83622-42-8 HCAPLUS
CN 1,3,2-Dioxaborolane, 2-(chloromethyl)-4,4,5,5-tetramethyl- (9CI) (CA INDEX NAME)



RN 94242-86-1 HCAPLUS
CN 1,3,2-Dioxaborolane, 2-(1-chloroethyl)-4,4,5,5-tetramethyl- (9CI) (CA INDEX NAME)



RN 95656-94-3 HCAPLUS
CN 3-Oxazolidinecarboxylic acid, 4-ethyl-5-oxo-, phenylmethyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 126689-01-8 HCAPLUS
CN 1,3,2-Dioxaborolane, 2-cyclopropyl-4,4,5,5-tetramethyl- (9CI) (CA INDEX NAME)



RN 131357-48-7 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole, 2-[(1S)-1-chloro-3-butenyl]hexahydro-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 131433-93-7 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole, hexahydro-3a,5,5-trimethyl-2-(2-propenyl)-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172096-96-7 HCAPLUS
CN 3-Oxazolidinecarboxylic acid, 4-(1-methylethyl)-5-oxo-, 1,1-dimethylethyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 319009-74-0 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, hexahydro-3a,5,5-

trimethyl-α-[1-(phenylmethoxy)ethyl]-, hydrochloride,
(αR,3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 319009-76-2 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, hexahydro-3a,5,5-trimethyl-α-[(phenylmethoxy)methyl]-, hydrochloride,
(αR,3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 319009-78-4 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, hexahydro-3a,5,5-trimethyl-α-[(phenylthio)methyl]-, hydrochloride, (3aS,4S,6S,7aR)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 319009-80-8 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, hexahydro-3a,5,5-trimethyl-α-[(phenyldithio)methyl]-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 319009-82-0 HCAPLUS
CN 1,3,2-Dioxaborolane-2-methanamine, 4,4,5,5-tetramethyl-α-(3,3,3-trifluoropropyl)- (9CI) (CA INDEX NAME)



RN 319009-90-0 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, hexahydro-3a,5,5-trimethyl-α-2-propenyl-, hydrochloride, (αR,3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 319009-92-2 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, α-ethylhexahydro-3a,5,5-trimethyl-, hydrochloride, (αR,3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 319009-94-4 HCAPLUS
CN 1,3,2-Dioxaborolane-2-methanamine, α-cyclopropyl-4,4,5,5-tetramethyl- (9CI) (CA INDEX NAME)



RN 319009-96-6 HCAPLUS
CN 1,3,2-Dioxaborolane-2-methanamine, α-(2,2-difluoroethyl)-4,4,5,5-tetramethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 319009-98-8 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, α-ethenylhexahydro-3a,5,5-trimethyl-, hydrochloride, (αR,3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 319010-99-6 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole, 2-[(1S)-1-chloropropyl]hexahydro-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 319011-02-4 HCAPLUS
CN 1,3,2-Dioxaborolane, 2-(chlorocyclopropylmethyl)-4,4,5,5-tetramethyl- (9CI) (CA INDEX NAME)



RN 319011-08-0 HCAPLUS
CN 1,3,2-Dioxaborolane, 2-[3,3-difluoro-1-(phenylthio)propyl]-4,4,5,5-tetramethyl- (9CI) (CA INDEX NAME)



RN 319011-10-4 HCAPLUS
CN 1,3,2-Dioxaborolane, 2-(3,3-difluoro-1-iodopropyl)-4,4,5,5-tetramethyl- (9CI) (CA INDEX NAME)



RN 319011-16-0 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole, hexahydro-3a,5,5-trimethyl-2-[1-(phenylmethoxy)ethyl]-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 319011-18-2 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole, 2-[(1S)-1-chloro-2-(phenylmethoxy)propyl]hexahydro-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 319011-22-8 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole, 2-[1-chloro-2-(phenylthio)ethyl]hexahydro-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 319011-25-1 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole, 2-[1-chloro-2-(phenyldithio)ethyl]hexahydro-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 319011-27-3 HCAPLUS
CN 1,3,2-Dioxaborolane, 4,4,5,5-tetramethyl-2-[4,4,4-trifluoro-1-(phenylthio)butyl]- (9CI) (CA INDEX NAME)



RN 319011-29-5 HCAPLUS
CN 1,3,2-Dioxaborolane, 4,4,5,5-tetramethyl-2-(4,4,4-trifluoro-1-iodobutyl)-(9CI) (CA INDEX NAME)



RN 323197-10-0 HCAPLUS
CN 3-Oxazolidinecarboxylic acid, 4-(1-methylethyl)-5-oxo-4-(2-propenyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 323197-11-1 HCAPLUS
CN 4-Pentenoic acid, 2-(1-methylethyl)-2-[[(phenylmethoxy)carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 323197-12-2 HCAPLUS
CN Valine, 2-(2-oxoethyl)-N-[(phenylmethoxy)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 323197-13-3 HCAPLUS
CN 1-Pyrrolidineacetic acid, α-(cyclohexylmethyl)-3-(1-methylethyl)-2-oxo-3-[[(phenylmethoxy)carbonyl]amino]-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-14-4 HCAPLUS
CN 1-Pyrrolidineacetic acid, 3-amino-α-(cyclohexylmethyl)-3-(1-methylethyl)-2-oxo-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-15-5 HCAPLUS
CN 1-Pyrrolidineacetic acid, α-(cyclohexylmethyl)-3-(1-methylethyl)-3-[[(2S)-3-methyl-1-oxo-2-[(pyrazinylcarbonyl)amino]butyl]amino]-2-oxo-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-16-6 HCAPLUS
CN 1-Pyrrolidineacetic acid, α-(cyclohexylmethyl)-3-(1-methylethyl)-3-[[(2S)-3-methyl-1-oxo-2-[(pyrazinylcarbonyl)amino]butyl]amino]-2-oxo-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-17-7 HCAPLUS
CN Norvaline, 5-hydroxy-2-(1-methylethyl)-N-[(phenylmethoxy)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 323197-18-8 HCAPLUS
CN Norvaline, 2-(1-methylethyl)-5-oxo-N-[(phenylmethoxy)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 323197-19-9 HCAPLUS
CN Cyclohexanepropanoic acid, α-[[4-(methoxycarbonyl)-5-methyl-4-[[(phenylmethoxy)carbonyl]amino]hexyl]amino]-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-20-2 HCAPLUS
CN 1-Piperidineacetic acid, α-(cyclohexylmethyl)-3-(1-methylethyl)-2-oxo-3-[[(phenylmethoxy)carbonyl]amino]-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-21-3 HCAPLUS
CN 1-Piperidineacetic acid, 3-amino-α-(cyclohexylmethyl)-3-(1-methylethyl)-2-oxo-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-22-4 HCAPLUS
CN 1-Piperidineacetic acid, α-(cyclohexylmethyl)-3-(1-methylethyl)-3-[[(2S)-3-methyl-1-oxo-2-[(pyrazinylcarbonyl)amino]butyl]amino]-2-oxo-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-23-5 HCAPLUS
CN 1-Piperidineacetic acid, α-(cyclohexylmethyl)-3-(1-methylethyl)-3-[[(2S)-3-methyl-1-oxo-2-[(pyrazinylcarbonyl)amino]butyl]amino]-2-oxo-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-24-6 HCAPLUS
CN Glycine, 4,5-didehydro-N-[(1,1-dimethylethoxy)carbonyl]norvalyl-N-2-propenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 323197-25-7 HCAPLUS
CN 1H-Azepine-1-acetic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2,3,4,7-tetrahydro-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 323197-26-8 HCAPLUS
CN 1H-Azepine-1-acetic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2,3,4,7-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)



RN 323197-27-9 HCAPLUS
CN Carbamic acid, [1-[2-[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]amino]-2-oxoethyl]hexahydro-2-oxo-1H-azepin-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-28-0 HCAPLUS
CN 1H-Azepine-1-acetamide, 3-amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]hexahydro-2-

oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-29-1 HCAPLUS
CN 1-Pyrrolidineacetic acid, α-(cyclohexylmethyl)-3-(1-methylethyl)-2-oxo-3-[[(phenylmethoxy)carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-30-4 HCAPLUS
CN Carbamic acid, [1-[(1S)-1-(cyclohexylmethyl)-2-[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]amino]-2-oxoethyl]-3-(1-methylethyl)-2-oxo-3-pyrrolidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-31-5 HCAPLUS
CN 1-Pyrrolidineacetic acid, 3-(1-methylethyl)-2-oxo-α-phenyl-3-[[(phenylmethoxy)carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-32-6 HCAPLUS
CN 1-Pyrrolidineacetic acid, 3-(1-methylethyl)-α-(2-methylpropyl)-2-oxo-3-[[(phenylmethoxy)carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-33-7 HCAPLUS
CN 3-Oxazolidinecarboxylic acid, 4-ethyl-5-oxo-4-(2-propenyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 323197-34-8 HCAPLUS
CN 4-Pentenoic acid, 2-ethyl-2-[[(phenylmethoxy)carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 323197-35-9 HCAPLUS
CN Butanoic acid, 2-ethyl-4-oxo-2-[[(phenylmethoxy)carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 323197-36-0 HCAPLUS
CN 1-Pyrrolidineacetic acid, α-(cyclohexylmethyl)-3-ethyl-2-oxo-3-[[(phenylmethoxy)carbonyl]amino]-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-37-1 HCAPLUS
CN 1-Pyrrolidineacetic acid, 3-amino-α-(cyclohexylmethyl)-3-ethyl-2-oxo-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-38-2 HCAPLUS
CN 1-Pyrrolidineacetic acid, α-(cyclohexylmethyl)-3-ethyl-3-[[(2S)-3-methyl-1-oxo-2-[(pyrazinylcarbonyl)amino]butyl]amino]-2-oxo-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-39-3 HCAPLUS
CN 1-Pyrrolidineacetic acid, α-(cyclohexylmethyl)-3-ethyl-3-[[(2S)-3-methyl-1-oxo-2-[(pyrazinylcarbonyl)amino]butyl]amino]-2-oxo-, (αS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-40-6 HCAPLUS
CN 3-Oxazolidinecarboxylic acid, 4-(1-methylethyl)-5-oxo-4-(2-propenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 323197-41-7 HCAPLUS
CN 4-Pentenoic acid, 2-[[(1,1-dimethylethoxy)carbonyl]amino]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 323197-42-8 HCAPLUS
CN 4-Pentenoic acid, 2-[[(1,1-dimethylethoxy)carbonyl]amino]-2-(1-methylethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 323197-43-9 HCAPLUS
CN Norvaline, N-[(1,1-dimethylethoxy)carbonyl]-5-hydroxy-2-(1-methylethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 323197-44-0 HCAPLUS
CN Norvaline, N-[(1,1-dimethylethoxy)carbonyl]-2-(1-methylethyl)-5-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 323197-45-1 HCAPLUS
CN Benzeneacetic acid, α-[[4-[[(1,1-dimethylethoxy)carbonyl]amino]-5-methyl-4-[(phenylmethoxy)carbonyl]hexyl]amino]-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-46-2 HCAPLUS
CN Benzeneacetic acid, α-[[4-carboxy-4-[[(1,1-dimethylethoxy)carbonyl]amino]-5-methylhexyl]amino]-, monomethyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-47-3 HCAPLUS
CN 1-Piperidineacetic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-3-(1-methylethyl)-2-oxo-α-phenyl-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-48-4 HCAPLUS
CN 1-Piperidineacetic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-3-(1-methylethyl)-2-oxo-α-phenyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 323197-74-6 HCAPLUS
CN 1-Pyrrolidineacetic acid, 3-(1-methylethyl)-2-oxo-α-phenyl-3-[[(phenylmethoxy)carbonyl]amino]-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:607748 HCAPLUS
DOCUMENT NUMBER: 133:335259
TITLE: 1-Aminocyclopropaneboronic Acid: Synthesis and Incorporation into an Inhibitor of Hepatitis C Virus NS3 Protease
AUTHOR(S): **Priestley, E. Scott; Decicco, Carl P.**
CORPORATE SOURCE: Department of Chemical and Physical Sciences, DuPont Pharmaceuticals Company, Wilmington, DE, 19880, USA
SOURCE: Organic Letters (2000), 2(20), 3095-3097
CODEN: ORLEF7; ISSN: 1523-7060
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 133:335259

AB The previously unreported α,α-disubstituted 1-aminoboronate esters have potential utility in peptidomimetic design, particularly against serine protease targets. A concise synthesis of 1-aminocyclopropaneboronate pinanediol ester is reported, and a peptidyl derivative has modest affinity (Ki = 1.6 μM) for hepatitis C NS3 protease. Analogs with iso-Pr and cyclohexyl in place of cyclopropyl were also prepared and tested.

IT **274918-51-3**, Boc-Asp(O-t-Bu)-Glu(O-t-Bu)-Val-Val-Pro-OH
RL: RCT (Reactant); RACT (Reactant or reagent)
(coupling with α,α-disubstituted 1-aminoboronate esters)

RN 274918-51-3 HCAPLUS
CN L-Proline, N-[(1,1-dimethylethoxy)carbonyl]-L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **58644-54-5**, N-Cyclopropylformamide
RL: RCT (Reactant); RACT (Reactant or reagent)
(dehydration with tosyl chloride and tributylamine)
RN 58644-54-5 HCAPLUS
CN Formamide, N-cyclopropyl- (9CI) (CA INDEX NAME)



IT **58644-53-4P**, Cyclopropyl isocyanide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(explosion hazard during reaction; preparation and lithiation followed by metathesis with triisopropyl borate in preparation of α,α-disubstituted 1-aminoboronate ester)
RN 58644-53-4 HCAPLUS
CN Cyclopropane, isocyano- (9CI) (CA INDEX NAME)



IT **5419-55-6**, Triisopropyl borate **18680-27-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(for preparation of α,α-disubstituted 1-aminoboronate esters)
RN 5419-55-6 HCAPLUS
CN Boric acid (H3BO3), tris(1-methylethyl) ester (9CI) (CA INDEX NAME)



RN 18680-27-8 HCAPLUS
CN Bicyclo[3.1.1]heptane-2,3-diol, 2,6,6-trimethyl-, (1S,2S,3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **149885-80-3**, NS3 Protease
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(hepatitis C virus; synthesis of α,α-disubstituted 1-aminoboronate esters and incorporation into inhibitor of)
RN 149885-80-3 HCAPLUS
CN Proteinase, polyprotein-processing, NS3 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **598-45-8**, Isopropyl isocyanide **931-53-3**, Cyclohexyl isocyanide
RL: RCT (Reactant); RACT (Reactant or reagent)
(lithiation followed by metathesis with triisopropyl borate in preparation of α,α-disubstituted 1-aminoboronate ester)
RN 598-45-8 HCAPLUS
CN Propane, 2-isocyano- (9CI) (CA INDEX NAME)



RN 931-53-3 HCAPLUS
CN Cyclohexane, isocyano- (9CI) (CA INDEX NAME)



IT **303191-80-2P 303191-81-3P 303191-82-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and activity as inhibitor of hepatitis C NS3 protease)

RN 303191-80-2 HCAPLUS
CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]cyclopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 303191-81-3 HCAPLUS
CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 303191-82-4 HCAPLUS
CN L-Prolinamide, L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]cyclohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **303191-71-1P 303191-72-2P 303191-73-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and conversion to amine hydrochloride using methanolic hydrogen chloride)
RN 303191-71-1 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole, hexahydro-2-(1-isocyanocyclopropyl)-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 303191-72-2 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole, hexahydro-2-(1-isocyano-1-methylethyl)-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 303191-73-3 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborole, hexahydro-2-(1-isocyanocyclohexyl)-3a,5,5-trimethyl-, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **303191-74-4P 303191-75-5P 303191-76-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and coupling with pentapeptide)
RN 303191-74-4 HCAPLUS
CN Cyclopropanamine, 1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 303191-75-5 HCAPLUS
CN 4,6-Methano-1,3,2-benzodioxaborol-2-methanamine, hexahydro-α,α,3a,5,5-pentamethyl-, hydrochloride, (3aS,4S,6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 303191-76-6 HCAPLUS
CN Cyclohexanamine, 1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT **303191-77-7P 303191-78-8P 303191-79-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deprotection of)
RN 303191-77-7 HCAPLUS
CN L-Prolinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]cyclopropyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 303191-78-8 HCAPLUS
CN L-Prolinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-1-methylethyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 303191-79-9 HCAPLUS
CN L-Prolinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-α-aspartyl-L-α-glutamyl-L-valyl-L-valyl-N-[1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]cyclohexyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	23.75	33.05

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.77	-2.77

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 11:55:08 ON 04 JUN 2004